Ant Group Launches AI-Powered Mobile App Zhixiaobao at 2024 INCLUSION·Conference on the Bund
5.9.2024 10:55:00 CEST | Business Wire | Press release
Other AI-powered products were also introduced to make AI more accessible for industries and consumers
At the 2024 INCLUSION · Conference on the Bund in Shanghai, Ant Group launched the Zhixiaobao mobile app, an AI life assistant that better connects users with all kinds of life services on the company’s digital life platform Alipay. The app is available for download from iOS and Android app stores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904932587/en/
Ant Group unveiled AI life assistant app – Zhixiaobao, at the 2024 INCLUSION · Conference on the Bund. (Graphic: Business Wire)
As an AI-native application powered by Ant Group’s BaiLing foundation model, Zhixiaobao is designed to make everyday tasks easier through user-friendly interactions. Through typing or voice chat in Zhixiaobao, users can order meals, hail taxis, book tickets, and discover local dining and entertainment options, accessing third-party services in Alipay more easily.
The app also provides a number of built-in AI agents, each with specific domain knowledge that makes them an expert in their own fields. For example, the “English Language Tutor” agent can help users make a learning plan and provide tips for learning the language. The “Fitness Pro” agent can help users design workout routines and come up with personalized training advice.
"The evolution of AI extends beyond mere technological progress, it’s about applying these advancements to practical, user-focused solutions. Alipay is committed to harnessing AI’s potential to improve the user experience, ensuring that AI assistants like Zhixiaobao become valuable tools in everyday life for all," said Cyril Han, President of Ant Group.
To use Zhixiaobao’s services, users can either download the dedicated mobile app, or simply pull down the home page of the Alipay app.
In addition to Zhixiaobao, Ant Group also introduced other AI-powered products and solutions at the INCLUSION Conference.
- An AI Agent Development Platform: A comprehensive, one-stop platform enabling merchants to create customized AI service agents which can be deployed in just one minute, without the need for coding. These agents can be effortlessly integrated into the Alipay mini-programs operated by merchants, the Alipay app, and the Zhixiaobao app.
- AI Healthcare Manager: An AI-powered platform that connects users to over 30 health services, including doctor recommendations, medical test result interpretation, in-hospital navigation, and personalized medical advice. The AI Healthcare Manager is supported by over 20 service providers, including Renji Hospital in Shanghai.
- Ant Bridge: An open platform that leverages advanced technologies including AI models and financial intelligence, to assist insurance companies in providing personalized responses to customer inquiries in real-time. The platform is designed to support insurers to enhance their service quality while boosting operational efficiency.
Ant Group unveiled its BaiLing foundation model in 2023. Over the past two years, Ant Group has accelerated the application of AI technologies in the Alipay app, serving hundreds of millions of users across various life service use cases, including travel, healthcare, and financial management.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904932587/en/
Contacts
Media Inquiries
Media Inquiries
Vick Li Wei
vick.lw@antgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom